EUVIMEDEUVIMED entdecken
Open Access

Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020

Alexander D Sherry, Andrew W Hahn, Zachary R McCaw, Joseph Abi Jaoude, Ramez Kouzy, Timothy A Lin, Bruce Minsky, C David Fuller, Tomer Meirson, Pavlos Msaouel, Ethan B Ludmir

JAMA Network Open · 2024

DOI: 10.1001/jamanetworkopen.2024.3379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Alexander D Sherry und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Medical Oncology, Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Subgroup analyses are often performed in oncology to investigate differential treatment effects and may even constitute the basis for regulatory approvals. Current understanding of the features, results, and quality of subgroup analyses is limited.

Objective

To evaluate forest plot interpretability and credibility of differential treatment effect claims among oncology trials. Design, Setting, and Participants This cross-sectional study included randomized phase 3 clinical oncology trials published prior to 2021. Trials were screened from ClinicalTrials.gov. Main Outcomes and Measures Missing visual elements in forest plots were defined as a missing point estimate or use of a linear x-axis scale for hazard and odds ratios. Multiplicity of testing control was recorded. Differential treatment effect claims were rated using the Instrument for Assessing the Credibility of Effect Modification Analyses. Linear and logistic regressions evaluated associations with outcomes.

Results

Among 785 trials, 379 studies (48%) enrolling 331 653 patients reported a subgroup analysis. The forest plots of 43% of trials (156 of 363) were missing visual elements impeding interpretability. While 4148 subgroup effects were evaluated, only 1 trial (0.3%) controlled for multiple testing. On average, trials that did not meet the primary end point conducted 2 more subgroup effect tests compared with trials meeting the primary end point (95% CI, 0.59-3.43 tests; P = .006). A total of 101 differential treatment effects were claimed across 15% of trials (55 of 379). Interaction testing was missing in 53% of trials (29 of 55) claiming differential treatment effects. Trials not meeting the primary end point were associated with greater odds of no interaction testing (odds ratio, 4.47; 95% CI, 1.42-15.55, P = .01). The credibility of differential treatment effect claims was rated as low or very low in 93% of cases (94 of 101). Conclusions and Relevance In this cross-sectional study of phase 3 oncology trials, nearly half of trials presented a subgroup analysis in their primary publication. However, forest plots of these subgroup analyses largely lacked essential features for interpretation, and most differential treatment effect claims were not supported. Oncology subgroup analyses should be interpreted with caution, and improvements to the quality of subgroup analyses are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medical OncologyNeoplasmsHumansCross-Sectional StudiesOdds RatioRandomized Controlled Trials as TopicClinical Trials, Phase III as Topic

Autor:innen und Institutionen

  • Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.
  • Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston.
  • Insitro, South San Francisco, San Francisco, California.
  • Department of Biostatistics, University of North Carolina at Chapel Hill.
  • Department of Radiation Oncology, Stanford University, Stanford, California.
  • Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Förderung

  • NCI NIH HHS

Zitieren

APA

Sherry, A. D., Hahn, A. W., McCaw, Z. R., Abi Jaoude, J., Kouzy, R., Lin, T. A., Minsky, B., Fuller, C. D., Meirson, T., Msaouel, P., & Ludmir, E. B. (2024). Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.3379

Vancouver

Sherry AD, Hahn AW, McCaw ZR, Abi Jaoude J, Kouzy R, Lin TA, et al. Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.3379

BibTeX
@article{Sherry2024,
  author = {Sherry, Alexander D and Hahn, Andrew W and McCaw, Zachary R and Abi Jaoude, Joseph and Kouzy, Ramez and Lin, Timothy A and Minsky, Bruce and Fuller, C David and Meirson, Tomer and Msaouel, Pavlos and Ludmir, Ethan B},
  title = {Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020},
  journal = {JAMA Network Open},
  year = {2024},
  doi = {10.1001/jamanetworkopen.2024.3379}
}
Kostenlos starten →